Aquiline Takes Flourish From MassMutual in Wealthtech PE Deal
Aquiline is buying a controlling stake in Flourish from MassMutual — a wealthtech platform behind 1,300+ RIA firms overseeing $2.6T+ in client assets.
Capital Markets
Explore how companies and governments raise money through equity and debt markets. Read coverage of financing, public offerings, transactions and market structure alongside educational guides. Find your way around ECMSource.
Ternus Takes Over Apple: What He Inherits on Day One
John Ternus is Apple CEO as of September 1, 2026. Here’s the $4.59T company he inherits — and the five open questions on day one.
Private Equity 101: How PE Funds Actually Work
How PE funds are structured: GPs, LPs, 2-and-20, carried interest, hurdle rate, and the distribution waterfall — with a worked example on a $1B fund.
Private Credit’s $27B Six Weeks: Hayfin, Comvest, Bridgepoint
Three direct-lending mega-funds closed over $27 billion since July — Hayfin, Comvest and Bridgepoint. Inside the wave reshaping private credit.
Reddit Joins the S&P 500 on Aug 18: Shares Pop 8.8%
S&P Dow Jones Indices adds Reddit (RDDT) to the S&P 500 effective Aug 18, 2026. Shares jumped 8.8% after-hours as passive funds prepared to buy.
Private Credit’s Q2 Cracks: Ares Caps ASIF Redemptions
Q2 2026 private-credit reads: Ares Capital core EPS $0.47, ASIF pro-rates 14.4% redemption bid, Proskauer default index 2.51%. Where the stress is showing up.
The Index Effect: How S&P 500 Additions Move Stocks
How S&P 500 inclusion moves a stock: the pre-announcement drift, run-up to effective date, decay after, and why the effect has shrunk since 2010.
SpaceX Prices $25B Inaugural Bond on $89B in Orders
SpaceX sold $25B across five tranches in its first-ever bond sale, drawing nearly $89B in orders and tightening spreads 25 bps from talk.
SK Hynix Plans Record $29B Nasdaq ADR Listing in July
SK Hynix will raise up to $29.43B via a Nasdaq ADR listing on July 10, eclipsing Alibaba’s 2014 NYC debut as the largest foreign-issuer ADR ever.
AbbVie Buys Apogee for $10.9B; ABBV Pops 6%
AbbVie agreed to buy Apogee Therapeutics for $10.9B all-cash at a 49% premium, adding IL-13 candidate zumilokibart to challenge Dupixent. ABBV rose 6%.